8-K: Silexion Therapeutics Expands SIL204 Development Plan Following Promising Preclinical Data

Silexion Therapeutics announces an expanded development plan for SIL204, integrating systemic and intratumoral administration for KRAS-driven pancreatic cancer, based on encouraging preclinical results.

Summary

• Silexion Therapeutics is expanding the development plan for its next-generation siRNA candidate, SIL204.
• The new strategy combines systemic administration to target metastatic progression with intratumoral administration to focus on primary tumors.
• This approach aims to provide a comprehensive treatment for KRAS-driven pancreatic cancer.
• The decision follows promising preclinical findings showing that systemic SIL204 administration significantly inhibits tumor growth in orthotopic models.
• The company plans to conduct additional toxicology and pharmacodynamic studies throughout 2025.
• Regulatory submissions to the Israel Ministry of Health are planned for the second half of 2025, and to the European Union in the first half of 2026.
• These submissions would initiate the next stage of clinical development for SIL204 in patients with advanced localized KRAS-driven pancreatic cancer.
• The expanded plan builds on Phase 2 clinical results from siG12DLoder and recent studies showing SIL204's ability to reduce metastases.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the expanded development plan and promising preclinical data, but tempered by the inherent risks and uncertainties associated with clinical-stage biotechnology companies.

Positives

• SIL204 demonstrates enhanced siRNA stability and broader activity compared to the first-generation product.
• Preclinical studies support the effectiveness of subcutaneous SIL204 in reducing metastases.
• The company has received guidance from the German Federal Institute for Drugs and Medical Devices (BfArM) on the Phase 2/3 trial design.
• SIL204 is stable in vitro for over 48 hours in human serum.
• SIL204 behaves synergistically with Fluorouracil and Irinotecan-Containing Chemotherapy.

Negatives

• The company is still in the development stage and has a limited operating history.
• Silexion has never generated any revenue from product sales and may never be profitable.
• The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.

Risks

• The company's ability to successfully complete preclinical studies and initiate clinical trials is uncertain.
• Future capital requirements and the ability to obtain additional capital pose a risk.
• The impact of the regulatory environment and compliance complexities could affect development.
• Expectations regarding future partnerships or other relationships with third parties may not materialize.
• The company's strategy, future operations, financial position, projected costs, prospects, and plans are subject to change.

Future Outlook

Silexion plans to initiate human trials for SIL204 in H1 2026 and is focused on advancing its integrated treatment regimen for KRAS-driven cancers.

Management Comments

• Our expanded development plan reflects the strength of recent preclinical data and our commitment to addressing the complexities of KRAS-driven cancers, said Ilan Hadar, Chairman and CEO of Silexion Therapeutics.
• By combining localized and systemic delivery strategies, we aim to offer a more comprehensive solution to one of the most challenging cancers to treat.
• With our goal of initiating human trials in the H1 2026, we look forward to advancing this approach into clinical trials and delivering meaningful progress for patients in need.

Industry Context

This announcement is relevant in the context of the ongoing efforts to develop targeted therapies for KRAS-driven cancers, which are prevalent and difficult to treat. The dual-route administration strategy reflects a growing understanding of the need to address both primary tumors and metastases in aggressive cancers.

Comparison to Industry Standards

• The company's first-generation product, siG12DLoder, demonstrated an overall survival benefit in Phase 2 clinical trials.
• SIL204 targets > 74% of KRAS mutations in PDAC while currently available KRAS G12C treatment are treating ~1.5%.
• The median overall survival for non-resectable PC populations is 14-17 months.
• Phase 2 clinical trial with first generation Loder in LAPC showed strong trend for 9.3 months improvement in survival.

Stakeholder Impact

• Shareholders may see potential for increased value due to the expanded development plan.
• Patients with KRAS-driven pancreatic cancer could benefit from a more comprehensive treatment approach.
• Employees are involved in advancing a promising therapeutic candidate.
• Potential partners may be interested in collaborating on the development and commercialization of SIL204.

Next Steps

• Conduct additional toxicology and pharmacodynamic studies throughout the remainder of 2025.
• Submit regulatory submissions to the Israel Ministry of Health in H2 2025 and to the European Union in H1 2026.
• Initiate Phase 2/3 clinical trials for SIL204 in H1 2026.

Key Dates

Keywords

SIL204, KRAS, Pancreatic Cancer, siRNA, RNAi, Oncology, Metastasis, Intratumoral, Systemic Administration, Clinical Trials